{"entity":{"id":"idea-fund-intraoperative-imaging-trials","kind":"idea","name":"A pragmatic trial network for intraoperative margin tools, paid on margin reduction","aka":[],"tldr":"Tools that show surgeons where the tumour ends during the operation could cut the number of patients who need a second operation, but none has been properly tested at scale. A network would run those trials and pay on results.","summary":"A standing network of surgical centres running randomised, pragmatic trials of fluorescence-guided surgery agents, intraoperative specimen imaging, optical and mass-spectrometry margin probes and AI-based margin prediction, with positive-margin and re-operation rates as primary endpoints and payer contracts that reimburse devices on demonstrated margin reduction. Several agents and devices are approved or near approval, but adoption is slow because evidence is single-centre and payers are unconvinced. The network would also standardise pathology margin assessment, which varies enough to confound trials.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Surgery and radiotherapy cure most, get least): Sullivan et al., Global cancer surgery (Lancet Oncology Commission 2015)","url":"https://doi.org/10.1016/S1470-2045(15)00223-5"}],"tags":[],"related":["idea-fund-device-and-technique-translation-fund","idea-fund-surgical-trials-network"],"cancers":["breast-hr-positive","head-and-neck","prostate"],"sections":[],"technologies":["fluorescence-guided-surgery","optical-imaging"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-surgery-radiation-innovation","b-translational-valley"],"keyPapers":["paper-sullivan-lancet-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"The network completes randomised trials of at least five intraoperative margin technologies within four years, at least two of which reduce positive margins or re-operation by a third in breast, head and neck or prostate surgery and are adopted under outcome-based payment.","rationale":"Re-operation rates after breast-conserving surgery run at a fifth in many systems; positive margins predict recurrence in most solid tumours. Pegulicianine and other agents have shown margin detection in trials, but comparative evidence across technologies and payment models is absent.","test":"Launch two randomised trials in breast and head and neck surgery with margin primary endpoints and a pilot outcome-based payment contract with one payer.","maturity":"early-clinical","actor":"clinic","cost":"medium","horizonYears":4},"route":"/ideas/idea-fund-intraoperative-imaging-trials/","neighbours":{"idea":[{"id":"idea-fund-surgical-trials-network","kind":"idea","name":"A permanently funded international network for randomised cancer surgery trials","route":"/ideas/idea-fund-surgical-trials-network/"},{"id":"idea-fund-device-and-technique-translation-fund","kind":"idea","name":"A translation fund for academic surgical devices and radiotherapy technology","route":"/ideas/idea-fund-device-and-technique-translation-fund/"}],"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"fluorescence-guided-surgery","kind":"technology","name":"Fluorescence-guided surgery","route":"/technologies/fluorescence-guided-surgery/"},{"id":"optical-imaging","kind":"technology","name":"Optical & fluorescence imaging","route":"/technologies/optical-imaging/"}],"bottleneck":[{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}],"paper":[{"id":"paper-sullivan-lancet-oncol","kind":"paper","name":"Global cancer surgery: delivering safe, affordable, and timely cancer surgery","route":"/key-papers/paper-sullivan-lancet-oncol/"}]}}